Glucagon-like peptide 1-based therapies and risk of pancreatitis: A self-controlled case series analysis

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 3, 2014, Pages 234-239

  Li, Xiaochun ^a   Zhang, Zuoyi ^b   Duke, Jon ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

Author keywords

Electronic observational databases; GPL 1; Pancreatitis; Pharmacoepidemiology; Safety surveillance; Self controlled case series

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SITAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; VENOM;

ADULT; AGED; ARTICLE; CASE STUDY; CONTROLLED STUDY; CURRENT PROCEDURAL TERMINOLOGY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; ICD-9; INCIDENCE; INCIDENCE DENSITY RATIO; MALE; MIDDLE AGED; PANCREATITIS; PARTICIPANT OBSERVATION; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SELF CONTROLLED CASE SERIES; SENSITIVITY ANALYSIS; CHEMICALLY INDUCED; COHORT ANALYSIS; FACTUAL DATABASE; TRENDS; YOUNG ADULT;

ADULT; AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; PEPTIDES; PYRAZINES; RISK FACTORS; TRIAZOLES; VENOMS; YOUNG ADULT;

EID: 84895474209     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3542     Document Type: Article

References (9)

1. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. Jul 2011; 141(1): 150-156.
2. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus a population-based matched case-control study. JAMA Intern Med. Apr 8 2013; 173(7): 534-539.
3. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. Apr 2009; 25(4): 1019-1027.
4. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab. Jul 2011; 96(7): 2027-2031.
5. Whitaker H. The self controlled case series method. BMJ 2008; 337: a1069.
6. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25: 1768-1797.
7. OMOP. OMOP common data model (CDM) specifications, 2009; Version 2.0.
8. Ryan PB. Establishing a drug era persistence window for active surveillance, 2010; http://omop.fnih.org/OMOPWhitePapers.
9. Ryan PB. Establishing a condition era persistence window for active surveillance, 2010; http://omop.fnih.org/OMOPWhitePapers.